OncoMatch/Clinical Trials/NCT05514275
Radiotherapy Combined With Endostatin and Capecitabine for NPC
Is NCT05514275 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Endostatin and Capecitabine for nasopharyngeal carcinoma.
Treatment: Endostatin and Capecitabine — Radiotherapy combined with recombinant human endostatin and capecitabine for patients with nasopharyngeal carcinoma (NPC) resistant to induction chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T3-4N1, N2-3 (8th American Joint Commission on Cancer edition)
Tumor staged as T3-4N1/N2-3 (according to the 8th American Joint Commission on Cancer edition). No evidence of distant metastasis (M0).
Demographics
Prior therapy
Must have received: neoadjuvant chemotherapy — neoadjuvant
unsatisfactory tumor response (stable or progressive disease) after neoadjuvant chemotherapy (NACT)
Cannot have received: chemotherapy
Exception: except neoadjuvant chemotherapy
Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes
Cannot have received: surgery
Exception: except diagnostic
Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes
Cannot have received: radiotherapy
Exception: except for non-melanomatous skin cancers outside intended RT treatment volume
History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume)
Lab requirements
Blood counts
leucocyte count ≥4000/μL, hemoglobin ≥90g/L, platelet count ≥100000/μL
Kidney function
creatinine clearance ≥60 ml/min
Liver function
ALT, AST <1.5×ULN; ALP ≤2.5×ULN; bilirubin ≤ULN
Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count ≥100000/μL. Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) <1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN. Adequate renal function: creatinine clearance ≥60 ml/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05514275 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T3-4N1 or N2-3 is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages